Efficacy and Tolerability of Meroplan S (Meropenem 1 g and Sulbactam 0.5 g) (ETIOS) in the Management of Lower Respiratory Tract Infections caused by Gram-negative Pathogens in Adults: A Post Marketing Observational Study.
Loading...
Date
2013-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: The rapid and ongoing spread of antimicrobial-resistant bacteria throughout all healthcare institutions is
considered a critical medical and public health issue. Gram-negative bacteria are resistant to multiple drugs and are increasingly
resistant to most available antibiotics. Given the high mortality rates caused by drug-resistant Gram-negative bacteria such as
Klebsiella, Acinetobacter, Pseudomonas aeruginosa and Escherichia coli and the difficulty of developing new potent antibiotics to
target the problematic pathogens, combination regimens are under ardent evaluation as new strategies to overcome increasing
drug resistance. Carbapenems such as meropenem have assumed an important antibiotic niche for therapy of various multidrugresistant
Gram-negative infections with good safety profile. However, the percentage of carbapenem-resistant enterobacteriaceae
(CRE) increased by 4-fold over the last decade and that one particular form of CRE, a resistant form of Klebsiella pneumoniae,
has increased 7-fold. Extended-release beta-lactamases (ESBL) production is one of the main bacterial resistance mechanisms to
carbapenem antibiotics. The use of ESBL inhibitors like sulbactam combined with carbapenem antibiotics allows the inactivation
of ESBLs produced by Gram-negative pathogens. Additionally, sulbactam has an intrinsic antimicrobial activity against penicillin
binding proteins. By restoring or expanding the activity of meropenem, the combination with sulbactam offers a new approach to
the management of lower respiratory tract infections caused by Gram-negative pathogens. A post marketing observational study
was undertaken to evaluate the efficacy and tolerability of (Meropenem 1 g and Sulbactam 0.5 g) injection in the management
of lower respiratory tract infections caused by Gram-negative pathogens in adults.
Description
Keywords
Meropenem, sulbactam, post marketing observational study, lower respiratory tract infections, Gramnegative pathogens
Citation
Braganza Lisa, Khandeparkar Prashant, Mukkadum Qayum. Efficacy and Tolerability of Meroplan S (Meropenem 1 g and Sulbactam 0.5 g) (ETIOS) in the Management of Lower Respiratory Tract Infections caused by Gram-negative Pathogens in Adults: A Post Marketing Observational Study. Indian Journal of Clinical Practice. 2013 Apr; 23(11): 721-727.